Talimogene Laherparepvec - National Cancer Institute

Talimogene Laherparepvec - National Cancer Institute

CANCER TREATMENT

• Types of Treatment
• Side Effects
• Clinical Trials Information for Patients and Caregivers
• A to Z List of Cancer Drugs
  • Drugs Approved for Different Types of Cancer
  • Drugs Approved for Conditions Related to Cancer
  • Off-Label Drug Use in Cancer Treatment
• Complementary & Alternative Medicine (CAM)
• Questions to Ask about Your Treatment
• Research

Talimogene Laherparepvec

• 
• 
• 
• 
• 
• 
• 

(tah-LIH-moh-jeen lah-HER-pah-REP-vek)

This page contains brief information about talimogene laherparepvec and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Imlygic

FDA Approved

Yes

FDA Approval for Talimogene Laherparepvec

Use in Cancer

Talimogene laherparepvec is approved to treat:

• Melanoma in the skin and lymph nodes that cannot be removed by surgery. It is used as local treatment in patients whose disease has recurred (come back) after being treated with surgery.

Talimogene laherparepvec is also being studied in the treatment of other types ofcancer.

More About Talimogene Laherparepvec

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results

Oncolytic Virus Therapy Shows Benefit in Patients with Melanoma - Information about the use of this drug to treat cancer.

Clinical Trials Accepting Patients

Find Clinical Trials for Talimogene Laherparepvec - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.